Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Godehard Scholz"'
Autor:
Jennifer Amsler, Iveta Kysela, Christoph Tappeiner, Luca Seitz, Lisa Christ, Godehard Scholz, Odile Stalder, Florian Kollert, Stephan Reichenbach, Peter M. Villiger
Publikováno v:
Arthritis Research & Therapy, Vol 23, Iss 1, Pp 1-8 (2021)
Abstract Objectives Giant cell arteritis (GCA) may lead to vision loss. To what extent tocilizumab (TCZ) is able to prevent vision loss is unknown. The aim was to analyze the occurrence of vision loss in a large GCA cohort treated with TCZ. Methods I
Externí odkaz:
https://doaj.org/article/57fdeeb9b45243a494569927ada3fdc5
Autor:
Godehard Scholz, Camilla Jandus, Lianjun Zhang, Camille Grandclément, Isabel C. Lopez-Mejia, Charlotte Soneson, Mauro Delorenzi, Lluis Fajas, Werner Held, Olivier Dormond, Pedro Romero
Publikováno v:
EBioMedicine, Vol 4, Iss C, Pp 50-61 (2016)
Robust, long-lasting immune responses are elicited by memory T cells that possess properties of stem cells, enabling them to persist long-term and to permanently replenish the effector pools. Thus, stem cell-like memory T (TSCM) cells are of key ther
Externí odkaz:
https://doaj.org/article/4e523409dbc649db8aa2508df7d23366
Autor:
Peter M. Villiger, Lisa Christ, Luca Seitz, Godehard Scholz, Christoph Tappeiner, Francesco Muratore, Carlo Salvarani, Sue Mollan, Vanessa Quick, Christian Dejaco, Michael Lee, Neil Basu, Neil Miller, John H. Stone
Publikováno v:
A Clinician's Pearls & Myths in Rheumatology ISBN: 9783031234873
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d939258c646a4fc31cc9ce2b9c302104
https://doi.org/10.1007/978-3-031-23488-0_27
https://doi.org/10.1007/978-3-031-23488-0_27
Autor:
Godehard Scholz, Jennifer Amsler, Odile Stalder, Lisa Christ, Christoph Tappeiner, Iveta Kysela, Luca Seitz, Peter M. Villiger, Stephan Reichenbach, Florian Kollert
Publikováno v:
Arthritis Research & Therapy, Vol 23, Iss 1, Pp 1-8 (2021)
Amsler, Jennifer; Kysela, Iveta; Tappeiner, Christoph; Seitz, Luca; Christ, Lisa; Scholz, Godehard; Stalder, Odile; Kollert, Florian; Reichenbach, Stephan; Villiger, Peter (2021). Vision loss in patients with giant cell arteritis treated with tocilizumab. Arthritis research & therapy, 23(1), p. 92. BioMed Central 10.1186/s13075-021-02480-4
Arthritis Research & Therapy
Amsler, Jennifer; Kysela, Iveta; Tappeiner, Christoph; Seitz, Luca; Christ, Lisa; Scholz, Godehard; Stalder, Odile; Kollert, Florian; Reichenbach, Stephan; Villiger, Peter (2021). Vision loss in patients with giant cell arteritis treated with tocilizumab. Arthritis research & therapy, 23(1), p. 92. BioMed Central 10.1186/s13075-021-02480-4
Arthritis Research & Therapy
Objectives Giant cell arteritis (GCA) may lead to vision loss. To what extent tocilizumab (TCZ) is able to prevent vision loss is unknown. The aim was to analyze the occurrence of vision loss in a large GCA cohort treated with TCZ. Methods In this ob
Autor:
Fabian Lötscher, Godehard Scholz, Adela-Cristina Sarbu, Lisa Christ, Peter M. Villiger, Wolfgang A. Schmidt, Florian Kollert, Lukas Bütikofer, Luca Seitz, Stephan Reichenbach
Publikováno v:
Seitz, Luca; Christ, Lisa; Lötscher, Fabian; Scholz, Godehard; Sarbu, Adela-Cristina; Bütikofer, Lukas; Kollert, Florian; Schmidt, Wolfgang A; Reichenbach, Stephan; Villiger, Peter M. (2021). Quantitative ultrasound to monitor the vascular response to tocilizumab in giant cell arteritis. Rheumatology, 60(11), pp. 5052-5059. Oxford University Press 10.1093/rheumatology/keab484
Rheumatology (Oxford, England)
Rheumatology (Oxford, England)
Objectives To characterize the effect of ultra-short glucocorticoids followed by Tocilizumab monotherapy on the intima-media thickness (IMT) in GCA. Methods Eighteen GCA patients received 500 mg for 3 consecutive days (total of 1500mg) i.v. methylpre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f28f2e5d9b13c1ce65ec9b7277d6c394
https://boris.unibe.ch/156887/8/Seitz_Rheumatology_Oxf__2021.pdf
https://boris.unibe.ch/156887/8/Seitz_Rheumatology_Oxf__2021.pdf
Autor:
Daniel Aeberli, Axel Finckh, Peter M. Villiger, Martin Fiedler, Almut Scherer, Burkhard Möller, Godehard Scholz, Uta Arndt, Cem Gabay, Diego Kyburz, Alexander Benedikt Leichtle
Publikováno v:
British Journal of Haematology, Vol. 186, No 1 (2019) pp. 101-112
Anaemia affects quality of life and radiographic outcome in rheumatoid arthritis (RA). In a cross-sectional study with 779 patients, we assessed the prognostic potential of the major haematopoietic regulators, hepcidin and erythropoietin, comparing t
Autor:
Peter M. Villiger, Stephan Reichenbach, Adela-Cristina Sarbu, Godehard Scholz, Lukas Bütikofer, Luca Seitz, Christoph Tappeiner, Florian Kollert, Lisa Christ, Jennifer Amsler
Summary Background Two randomised controlled trials showed a glucocorticoid-sparing effect of tocilizumab in patients with giant cell arteritis. In the GUSTO trial we aimed to evaluate the efficacy and safety of tocilizumab monotherapy after ultra-sh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1236bc876ffd74a327e2d1784f40d0a8
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85113288768
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85113288768
Autor:
Francesca Biondo, Carol A. Connell, Jose Luis Rivas, Harry Shi, Godehard Scholz, B. Moeller, Sander Strengholt, Axel Finckh, Jose-Maria Alvaro-Gracia, Daniel Aletaha
Publikováno v:
Poster Presentations.
Autor:
Luca Seitz, Jennifer Amsler, Christoph Tappeiner, Adela-Cristina Sarbu, Godehard Scholz, Lukas Bütikofer, Florian Kollert, Stephan Reichenbach, Lisa Christ, Peter M. Villiger
Publikováno v:
Annals of the Rheumatic Diseases. 80:33.2-33
Background:Two randomised controlled trials [1, 2] demonstrated a glucocorticoid (GC)-sparing effect of tocilizumab (TCZ) of at least 50%. Long-term GC treatment leads invariably to numerous side effects, particularly in elderly giant cell arteritis
Autor:
Godehard Scholz, Burkhard Möller
Publikováno v:
Zeitschrift für Rheumatologie. 76:21-26
Immunmodulierende Langzeitbehandlungen sind auch fur Spondyloarthritiden (SpA) einschlieslich Psoriasisarthritis (PsA) zur Standardbehandlung geworden. Es bestehen jedoch Fragen zur Dosisreduktion oder zum Behandlungsstopp bei wenig aktiver oder inak